ACXP News and Press, Acurx Pharmaceuticals Inc. From 03/16/22

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT PR Newswire STATEN ISLAND, N.Y. , March 16, 2022 /PRNewswire/ -- Acurx Pharmaceuticals...

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update Enrollment has started in Phase 2b trial of Ibezapolstat in Patients with C. difficile Infection PR Newswire STATEN ISLAND, N.Y. , March 7, 2022 /...

Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases PR Newswire STATEN ISLAND, N.Y. , Feb. 7, 2022 /PRNewswire/ -- Publication of study presents: Clinical results of 10 of 10 ...

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) - First patient enrolled in Phase 2b comparative trial segment vs vancomycin, current standard of care - Previously completed Ph...

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2021 Earnings Conference Call Nov 15, 2021 08:30 AM ET Company Participants David Luci - President and CEO Robert Shawah - Co-Founder and CFO Conference Call Participants Jason McCarthy - Maxim Group Presentation Operator [Technical Difficulty] David Luci...

Acurx Pharmaceuticals (NASDAQ:ACXP): Q3 GAAP EPS of -$0.46. Cash of $14.5M Press Release For further details see: Acurx Pharmaceuticals reports Q3 results

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Nov. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stag...

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference PR Newswire STATEN ISLAND, N.Y. , Nov. 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acur...

Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , Oct. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the ...

Gainers: Xenon Pharmaceuticals XENE +76%, Milestone Scientific (NYSE:MLSS) +15%, Clene (NASDAQ:CLNN) +12%, OpGen OPGN +11%, Adverum Biotechnologies ADVM +8%. Losers: Owlet (NYSE:OWLT) -25, REGENXBIO (NASDAQ:RGNX) -21%, Omeros (NASDAQ...